Australian Man Survives Over 100 Days with Total Artificial Heart

In a world-first breakthrough, an Australian man has survived over 100 days with a total artificial heart, a feat made possible by the innovative BiVACOR Total Artificial Heart developed by Australian biomedical engineer Dr Daniel Timms. Implanted at St Vincent’s Hospital, Sydney, this revolutionary device has not only given hope to thousands of patients with end-stage heart failure, but also put Australia at the forefront of cardiac technology and clinical research.

The BiVACOR device is a fully implantable titanium artificial heart that mimics the natural function of a biological heart through magnetic levitation technology. Unlike traditional mechanical pumps or partial-support devices like Left Ventricular Assist Devices (LVADs), which can cost upwards of $100,000 per implant, BiVACOR replaces the heart entirely, offering more precise blood flow control and reduced wear and tear over time.

The patient, whose identity has been kept confidential, lived with the artificial heart for more than three months, even returning home post-surgery, an extraordinary achievement that surpasses previous attempts globally with similar total-heart technologies.

According to St Vincent’s Hospital, which led the procedure, the trial is part of a growing body of early-stage human testing backed by a combination of government funding, hospital grants, and private investment. Although exact figures have not been disclosed, hospitalisation for heart failure in Australia can cost between $1,500 and $3,000 per day, especially when intensive care is involved. A total artificial heart could significantly reduce long-term hospital dependency if patients can safely return home, as seen in this case.

While the United States is often seen as the hub for biomedical trials, Australia has quietly built a global reputation for fast-tracked innovation, thanks to its more agile regulatory framework and strong public-private clinical collaboration. BiVACOR, founded in Brisbane before relocating part of its research base to Houston, chose to conduct this landmark trial in Sydney due to both homegrown talent and smoother approval pathways with Australia’s Therapeutic Goods Administration (TGA).

Although the TGA has not yet greenlit widespread commercial use, additional human trials are under discussion both in Australia and overseas. BiVACOR’s leadership, including CEO Jim Dillon and founder Dr Daniel Timms, has indicated that the success of this case could accelerate applications for broader trial phases across key international markets.

Speaking to The Sydney Morning Herald, Dillon praised the collaboration between clinicians and engineers. “This isn’t just a medical first—it’s a technological and humanitarian leap,” he said. “We’re moving from supporting patients in ICUs to potentially giving them their lives back.”

Australian medical authorities have also hailed the development. A spokesperson for the National Heart Foundation noted the long-term implications: “With donor heart shortages globally, a viable, long-term artificial heart could transform transplant medicine forever.”

So, what’s next for BiVACOR?

If approved for commercial use, the device could reshape treatment models for patients deemed ineligible for donor transplants. Current assistive devices like LVADs often come with complications such as blood clots and limited lifespan. The magnetically suspended rotor in BiVACOR’s device removes most of these risks and enables continuous, adaptive flow based on patient needs.

It’s also worth noting that Australia’s government has pledged to boost investment into advanced medtech research, which may accelerate timelines for this and similar innovations. Discussions are already underway between BiVACOR and regulatory bodies on establishing clear approval milestones, although no formal date for the next patient trial has been publicly announced.

At this stage, no other Australian patients have been confirmed to have undergone the same procedure, but the success of this first case has fuelled optimism. Public response has been equally strong, with cardiac advocacy groups urging greater transparency around cost, access, and timelines for future rollout.With cardiovascular disease remaining one of the leading causes of death in Australia, the BiVACOR artificial heart could eventually become a life-saving option for thousands. As research continues, this breakthrough may mark the beginning of a new chapter in treating heart failure—not just as a condition to be managed, but one that could potentially be overcome.